Table 4.
Factors associated with the occurrence of TB during follow-up.
| Crude hazard ratio | Adjusted hazard ratio | |||
|---|---|---|---|---|
| Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | |
| Age‡ | 1.02 (0.99–1.03) | 0.087 | 1.01 (0.99–1.03) | 0.412 |
| SEX‡ | ||||
| Male | 1.55 (0.89–2.69) | 0.119 | 1.48 (0.85–2.60) | 0.168 |
| Female | 1.00 (Ref) | 1.00 (Ref) | ||
| DIAGNOSIS‡ | ||||
| MPA | 3.45 (1.16–10.26) | 0.026 | 3.22 (1.04–9.99) | 0.043 |
| GPA | 4.58 (1.54–13.62) | 0.006 | 4.63 (1.53–14.02) | 0.007 |
| EGPA | 1.00 (Ref) | 1.00 (Ref) | ||
| PAN | 3.20 (1.04–9.81) | 0.042 | 3.51 (1.13–10.88) | 0.030 |
| INSURANCE STATUS‡ | ||||
| National health insurance | 1.00 (Ref) | 1.00 (Ref) | ||
| Medical aid | 0.95 (0.23–3.91) | 0.946 | 1.06 (0.29–3.87) | 0.926 |
| COMORBIDITIES‡ | ||||
| Hypertension | 1.49 (0.86–2.59) | 0.156 | 1.11 (0.58–2.11) | 0.751 |
| Diabetes mellitus | 1.31 (0.74–2.32) | 0.346 | 1.06 (0.57–1.96) | 0.852 |
| Chronic kidney disease | 2.20 (1.13–4.29) | 0.021 | 1.77 (0.83–3.75) | 0.138 |
| Chronic obstructive pulmonaryDisease | 1.23 (0.60–2.53) | 0.568 | 1.45 (0.68–3.08) | 0.336 |
| IMMUNOSUPPRESSIVE AGENTS USAGE† | ||||
| Glucocorticoid usage ≥ 12 month | 0.86 (0.30–2.50) | 0.787 | 1.10 (0.36–3.30) | 0.870 |
| Cyclophosphamide | 0.87 (0.49–1.54) | 0.628 | 0.76 (0.41–1.40) | 0.381 |
| Azathioprine | 0.64 (0.32–1.31) | 0.222 | 0.62 (0.30–1.28) | 0.199 |
| Methotrexate | 1.11 (0.50–2.44) | 0.799 | 1.01 (0.44–2.33) | 0.974 |
| Rituximab | 1.12 (0.37–3.35) | 0.840 | 0.91 (0.29–2.82) | 0.871 |
‡
Age, sex, type of diagnosis, insurance status, and comorbidities were included as time-fixed variables.
Glucocorticoid usage ≥12 months, cyclophosphamide, azathioprine, methotrexate, and rituximab usage were included as time-dependent variables.
TB, tuberculosis; CI, confidence interval; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; PAN, polyarteritis nodosa.